Pacific Biosciences of California (Pacific Biosciences of California) Long-Term Capital Lease Obligation : $31.6 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California Long-Term Capital Lease Obligation?

Pacific Biosciences of California's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.6 Mil.

Pacific Biosciences of California's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($36.6 Mil) to Sep. 2023 ($34.1 Mil) and declined from Sep. 2023 ($34.1 Mil) to Dec. 2023 ($31.6 Mil).

Pacific Biosciences of California's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($50.0 Mil) to Dec. 2022 ($41.1 Mil) and declined from Dec. 2022 ($41.1 Mil) to Dec. 2023 ($31.6 Mil).

Pacific Biosciences of California Long-Term Capital Lease Obligation Historical Data

The historical data trend for Pacific Biosciences of California's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Long-Term Capital Lease Obligation Chart

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

41.96

37.67

49.97

41.07

31.61

Pacific Biosciences of California Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															41.07	38.97	36.60	34.10	31.61

Pacific Biosciences of California (NAS:PACB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Pacific Biosciences of California Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

P09:Germany P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Executives

Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025